SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,647.19 (-2.60%)
DOW   29,340.96 (-1.96%)
QQQ   270.01 (-3.49%)
AAPL   140.73 (-3.23%)
MSFT   235.30 (-4.66%)
META   134.43 (-3.34%)
GOOGL   99.07 (-2.32%)
AMZN   114.98 (-4.42%)
TSLA   223.19 (-6.27%)
NVDA   122.51 (-6.69%)
NIO   13.60 (-7.92%)
BABA   81.15 (-3.76%)
AMD   60.36 (-11.04%)
T   15.07 (-1.63%)
MU   53.42 (-2.20%)
CGC   3.02 (-19.47%)
F   12.13 (-1.86%)
GE   64.70 (-2.30%)
DIS   97.10 (-2.94%)
AMC   6.53 (-8.29%)
PYPL   90.33 (-4.33%)
PFE   42.50 (-1.37%)
NFLX   230.21 (-4.09%)
S&P 500   3,647.19 (-2.60%)
DOW   29,340.96 (-1.96%)
QQQ   270.01 (-3.49%)
AAPL   140.73 (-3.23%)
MSFT   235.30 (-4.66%)
META   134.43 (-3.34%)
GOOGL   99.07 (-2.32%)
AMZN   114.98 (-4.42%)
TSLA   223.19 (-6.27%)
NVDA   122.51 (-6.69%)
NIO   13.60 (-7.92%)
BABA   81.15 (-3.76%)
AMD   60.36 (-11.04%)
T   15.07 (-1.63%)
MU   53.42 (-2.20%)
CGC   3.02 (-19.47%)
F   12.13 (-1.86%)
GE   64.70 (-2.30%)
DIS   97.10 (-2.94%)
AMC   6.53 (-8.29%)
PYPL   90.33 (-4.33%)
PFE   42.50 (-1.37%)
NFLX   230.21 (-4.09%)
S&P 500   3,647.19 (-2.60%)
DOW   29,340.96 (-1.96%)
QQQ   270.01 (-3.49%)
AAPL   140.73 (-3.23%)
MSFT   235.30 (-4.66%)
META   134.43 (-3.34%)
GOOGL   99.07 (-2.32%)
AMZN   114.98 (-4.42%)
TSLA   223.19 (-6.27%)
NVDA   122.51 (-6.69%)
NIO   13.60 (-7.92%)
BABA   81.15 (-3.76%)
AMD   60.36 (-11.04%)
T   15.07 (-1.63%)
MU   53.42 (-2.20%)
CGC   3.02 (-19.47%)
F   12.13 (-1.86%)
GE   64.70 (-2.30%)
DIS   97.10 (-2.94%)
AMC   6.53 (-8.29%)
PYPL   90.33 (-4.33%)
PFE   42.50 (-1.37%)
NFLX   230.21 (-4.09%)
S&P 500   3,647.19 (-2.60%)
DOW   29,340.96 (-1.96%)
QQQ   270.01 (-3.49%)
AAPL   140.73 (-3.23%)
MSFT   235.30 (-4.66%)
META   134.43 (-3.34%)
GOOGL   99.07 (-2.32%)
AMZN   114.98 (-4.42%)
TSLA   223.19 (-6.27%)
NVDA   122.51 (-6.69%)
NIO   13.60 (-7.92%)
BABA   81.15 (-3.76%)
AMD   60.36 (-11.04%)
T   15.07 (-1.63%)
MU   53.42 (-2.20%)
CGC   3.02 (-19.47%)
F   12.13 (-1.86%)
GE   64.70 (-2.30%)
DIS   97.10 (-2.94%)
AMC   6.53 (-8.29%)
PYPL   90.33 (-4.33%)
PFE   42.50 (-1.37%)
NFLX   230.21 (-4.09%)
NASDAQ:FBIO

Fortress Biotech - FBIO Stock Forecast, Price & News

$0.86
-0.04 (-4.30%)
(As of 10/7/2022 12:04 PM ET)
Add
Compare
Today's Range
$0.85
▼
$0.89
50-Day Range
$0.77
▼
$1.29
52-Week Range
$0.75
▼
$3.69
Volume
1,900 shs
Average Volume
191,005 shs
Market Capitalization
$92.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.60

Fortress Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,029.4% Upside
$9.60 Price Target
Short Interest
Healthy
0.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of Fortress Biotech in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.90) to ($1.20) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

503rd out of 1,075 stocks

Pharmaceutical Preparations Industry

223rd out of 537 stocks

See Top Rated MarketRank™ Stocks Here
FBIO stock logo

About Fortress Biotech (NASDAQ:FBIO) Stock

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Stock News Headlines

October 6, 2022 | markets.businessinsider.com
EQS-News: Fortress Bios Portfolio Of Marketed Drugs Could Soon See Three Additions
October 6, 2022 | finance.yahoo.com
Fortress Bio’s Portfolio Of Marketed Drugs Could Soon See Three Additions
October 5, 2022 | benzinga.com
Fortress Bio's Portfolio Of Marketed Drugs Could Soon See Three Additions
October 5, 2022 | finance.yahoo.com
Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
September 8, 2022 | msn.com
Fortress Biotech Earnings Perspective: Return On Capital Employed
September 8, 2022 | finance.yahoo.com
Fortress Biotech to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 22, 2022 | nasdaq.com
Fortress Biotech Series A Cumulative Redeemable Perpetual Preferred Stock Shares Cross 11.5% Yield Mark
August 12, 2022 | finance.yahoo.com
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
August 11, 2022 | finance.yahoo.com
Fortress Biotech (FBIO) Reports Q2 Loss, Misses Revenue Estimates
August 11, 2022 | finance.yahoo.com
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation
August 11, 2022 | finance.yahoo.com
Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
August 11, 2022 | finance.yahoo.com
Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
August 9, 2022 | finance.yahoo.com
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
August 3, 2022 | finance.yahoo.com
Journey Medical Corporation to Announce Second Quarter 2022 Financial Results on August 9, 2022
July 27, 2022 | finance.yahoo.com
Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency
July 23, 2022 | finance.yahoo.com
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shift From Loss To Profit
July 22, 2022 | finance.yahoo.com
Fortress Biotech Appoints David Jin as Chief Financial Officer
July 14, 2022 | benzinga.com
B. Riley Securities Maintains Buy Rating for Fortress Biotech: Here's What You Need To Know
July 2, 2022 | finance.yahoo.com
Fortress Biotech, Inc. (FBIO)
June 16, 2022 | finance.yahoo.com
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma
June 8, 2022 | finance.yahoo.com
Do Institutions Own Fortress Biotech, Inc. (NASDAQ:FBIO) Shares?
June 6, 2022 | finance.yahoo.com
Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2022 | finance.yahoo.com
Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States
May 23, 2022 | finance.yahoo.com
Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference
May 19, 2022 | finance.yahoo.com
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
See More Headlines
Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Company Calendar

Last Earnings
11/15/2021
Today
10/07/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FBIO
CUSIP
21976U10
CIK
1429260
Web
www.fortressbiotech.com
Phone
(781) 652-4500
Fax
781-652-4545
Employees
173
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.60
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+1,013.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-64,700,000.00
Net Margins
-108.87%
Pretax Margin
-264.45%
Return on Equity
-45.90%
Return on Assets
-22.70%

Debt

Debt-to-Equity Ratio
0.61
Current Ratio
2.85
Quick Ratio
2.70

Sales & Book Value

Annual Sales
$68.79 million
Price / Sales
1.35
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.27 per share
Price / Book
0.38

Miscellaneous

Outstanding Shares
107,740,000
Free Float
79,401,000
Market Cap
$92.86 million
Optionable
Optionable
Beta
1.98

Key Executives

  • Dr. Lindsay Allan Rosenwald (Age 67)
    Exec. Chairman, Pres & CEO
    Comp: $92.65k
  • Mr. Michael S. Weiss Esq. (Age 56)
    Vice Chairman & Exec. Vice Chairman of Strategic Devel.
    Comp: $92.65k
  • Dr. George C. Avgerinos (Age 68)
    Sr. VP of Biologics Operations
    Comp: $524.35k
  • Ms. Robyn M. Hunter (Age 60)
    Exec. Officer
    Comp: $555.31k
  • Mr. David Jin
    CFO & Head of Corp. Devel.
  • Mr. Samuel Berry
    Gen. Counsel & Corp. Sec.
  • Dr. Thomas F. Schaible
    Project Leader of Inflammatory Bowel Disease

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













FBIO Stock - Frequently Asked Questions

Should I buy or sell Fortress Biotech stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FBIO shares.
View FBIO analyst ratings or view top-rated stocks.

What is Fortress Biotech's stock price forecast for 2022?

6 Wall Street research analysts have issued 1 year price objectives for Fortress Biotech's stock. Their FBIO share price forecasts range from $6.00 to $20.00. On average, they expect the company's stock price to reach $9.60 in the next twelve months. This suggests a possible upside of 966.0% from the stock's current price.
View analysts price targets for FBIO or view top-rated stocks among Wall Street analysts.

How have FBIO shares performed in 2022?

Fortress Biotech's stock was trading at $2.50 on January 1st, 2022. Since then, FBIO stock has decreased by 64.0% and is now trading at $0.9006.
View the best growth stocks for 2022 here.

When is Fortress Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our FBIO earnings forecast.

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) released its quarterly earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.06. The biopharmaceutical company earned $21.09 million during the quarter, compared to the consensus estimate of $18.41 million. Fortress Biotech had a negative trailing twelve-month return on equity of 45.90% and a negative net margin of 108.87%.

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

How do I buy shares of Fortress Biotech?

Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $0.90.

How much money does Fortress Biotech make?

Fortress Biotech (NASDAQ:FBIO) has a market capitalization of $97.03 million and generates $68.79 million in revenue each year. The biopharmaceutical company earns $-64,700,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis.

How many employees does Fortress Biotech have?

The company employs 173 workers across the globe.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.fortressbiotech.com. The biopharmaceutical company can be reached via phone at (781) 652-4500, via email at ir@fortressbiotech.com, or via fax at 781-652-4545.

This page (NASDAQ:FBIO) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.